C hronic hepatitis C virus (HCV) infection is a common bloodborne infection affecting an estimated 71 million persons globally and is associated with substantial morbidity and mortality because of complications of end-stage liver disease and hepatocellular carcinoma. 1, 2 Achieving a sustained virologic response (SVR) after antiviral treatment for HCV is associated with a decrease in liver-related morbidity and mortality. 3, 4 Among the 7 HCV genotypes (GTs), HCV GT1 is the most prevalent, with an estimated 83.4 million GT1-infected persons worldwide, representing 46.2% of the total. 5, 6 In part because of poor tolerability and low efficacy of historic regimens such as pegylated interferon (PegIFN) plus ribavirin (RBV), few patients initiated and completed treatment, of whom only a subset achieved SVR. 7 The emergence of all-oral, direct-acting antiviral drug (DAA) regimens with superior safety and efficacy in 2014 prompted the expansion of HCV treatment in real-world clinical settings. 8, 9 The fixed-dose combination of ledipasvir (LDV), a NS5A inhibitor, and sofosbuvir (SOF), a pangenotypic NS5B nucleotide polymerase inhibitor, was approved by the U.S. Food and Drug Administration in 2014. 10 For patients with HCV GT1, the safety and efficacy of LDV/SOF were demonstrated in a series of three phase 3 clinical trials, including ION-1, ION-2, and ION-3. [11] [12] [13] Although overall SVR rates for HCV GT1 exceeded 90%, differences in SVR were observed among GT1 treatmentexperienced patients with compensated cirrhosis, in whom 12 weeks of LDV/SOF or LDV/SOF/RBV resulted in SVR in 18 of 22 (82%) and 19 of 22 (86%) patients, respectively; and 24 weeks of LDV/SOF or LDV/SOF/ RBV achieved SVR in 22 of 22 (100%) and 22 of 22 (100%) patients, respectively. 12 A subsequent French trial of GT1 cirrhotic patients who failed telaprevir or boceprevir-based triple therapy regimens, as well as post hoc pooled analysis of phase 2/3 trials, revealed similar SVR rates among patients receiving LDV/SOF for 24 weeks or LDV/SOF/RBV for 12 weeks. 14, 15 On this basis, a 12-week regimen of LDV/SOF/RBV or 24-week regimen of LDV/SOF was recommended for GT1 cirrhotic patients who failed prior PegIFN/RBV in treatment guidelines of the American Association for the Study of Liver Diseases, Infectious Diseases Society of America, Canadian Association for the Study of Liver, and European Association for the Study of Liver. [16] [17] [18] Data confirming real-world results in this important subgroup of patients outside clinical trials are limited.
The aim of this study was to investigate the safety and effectiveness of LDV/SOF for 12 or 24 weeks, with or without RBV, in the treatment of HCV GT1 treatmentexperienced cirrhotic patients in HCV-TARGET, an international, prospective observational study within a consortium of academic and community sites, designed to examine all-oral DAA regimens in routine clinical practice. 19 
Materials and Methods

Patients
HCV-TARGET is a prospective, longitudinal, observational study of patients with chronic HCV undergoing antiviral therapy within an international consortium of academic (n ¼ 39) and community (n ¼ 18) centers from the United States, Canada, Germany, and Israel. Patients with chronic GT1 HCV infection aged 18 years or older who had clinical evidence of cirrhosis, failed prior interferon-based antiviral therapy (PegIFN AE ribavirin, boceprevir plus PegIFN/RBV, telaprevir plus PegIFN/RBV, SOF plus PegIFN/RBV, simeprevir plus PegIFN/RBV), and initiated antiviral therapy with LDV/SOF or LDV/SOF/ RBV were included. All patients provided informed consent within 4 weeks of treatment initiation. This study analysis was restricted to patients who started LDV/ SOF-based treatment before September 15, 2016.
Treatment Regimen
The choice of treatment regimen and duration was made by the treating physician. All patients included in this analysis received a fixed-dose combination of 1 LDV/SOF tablet (90 mg/400 mg) taken once daily. Dosing for RBV was determined at the discretion of the treating physician, although it was most commonly weight-based (1000 mg daily in divided doses if <75 kg; 1200 mg daily in divided doses if !75 kg). Treatment duration was defined as 12 weeks (AE7 days), 24 weeks (AE7 days), or other duration.
Data Collection
Redacted medical records including standard demographic, clinical, and virologic data were prospectively collected by a Centralized Chart Data Abstraction Team of trained coders at the Clinical Coordinating Center at the University of Florida by using a novel, standardized source data abstraction that has been described previously. 20 The collected data were managed by using secure, Web-based Research Electronic Data Capture (REDCap) tools hosted at the University of North Carolina, Chapel Hill and then reviewed for completeness and accuracy. 21 Baseline and updated demographic, clinical, adverse event, and virologic data were collected at the time of treatment initiation and every 12 weeks if available through end of treatment and post-treatment. Cirrhosis was defined by previously established criteria of the HCV-TARGET consortium [22] [23] [24] ; the primary indicator of cirrhosis was liver biopsy with METAVIR score F4. In its absence, cirrhosis was established on the basis of transient elastography (Fibroscan; Echosens, Paris, France) demonstrating median liver stiffness measurement !12.5 kPa, METAVIR score F3 with at least 1 secondary indicator (serum fibrosis scores above thresholds for cirrhosis, signs of portal hypertension including esophagogastric varices, portal gastropathy, or platelet count <140,000/mL), or !2 secondary indicators. Decompensated cirrhosis was defined by the presence of prior or current ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatic hydrothorax, variceal hemorrhage, or the documentation of the use of medications with indication specific to these complications. Adverse events (AEs) were defined as any new symptom or event captured in the medical record during the treatment period, independent of the requirement for dose reduction, treatment discontinuation, or a corrective prescription medication. All AEs were entered into the centralized database and coded in accordance with Medical Dictionary for Regulatory Activities terminology. The AE of anemia was defined as physician-reported anemia event, RBV dose reduction, administration of an erythropoietin-stimulating agent, or blood transfusion. Serious AEs or suspected unexpected serious adverse reactions were defined as any AE requiring hospitalization or met criteria for expedited reporting in accordance with Food and Drug Administration form MedWatch 3500.
Efficacy and Safety End Points
The primary efficacy end point was SVR, which was defined as HCV RNA below lower limit of quantification or undetectable at minimum 64 days after end of treatment (SVR12), to account for window of evaluation surrounding clinic visits. The per-protocol population (PP) (N ¼ 610) for analysis was restricted to patients who completed 12 or 24 weeks of treatment (AE2 weeks) and had final virologic outcomes available. Safety end points were evaluated in patients who completed 12 or 24 weeks of treatment (AE2 weeks) and had either final virologic outcomes available or who died or were lost during post-treatment follow-up (counted as non-virologic failures) and made up the evaluable population (EP) (N ¼ 634).
Statistical Analysis
Demographics, baseline laboratory values, treatment outcomes, and frequencies of AEs were collected and analyzed in EP population and according to duration of treatment (12 and 24 weeks). Virologic outcomes and associations between SVR and baseline covariates of interest were evaluated by c 2 and logistic regression in PP population, focusing on patients who received either 12-or 24-week regimens (n ¼ 589). Covariates identified as significant on logistic regression without influential collinearity were then singularly evaluated in multivariate models (age and sex always included) by using Firth penalized maximum likelihood estimation of predictors of SVR for LDV/SOF patients. Predictor variables of interest were selected a priori and included gender, age, race, Model for End-Stage Liver Disease (MELD), albumin (g/dL), platelet count (1000/mL), total bilirubin (mg/dL), RBV dose at baseline (mg/kg), RBV dose reduction, and history of hepatic decompensation. Patients who failed to complete treatment for any reason or were lost to follow-up during treatment were excluded from analysis. Results are presented as odds ratios (ORs) with corresponding 95% confidence interval (CI). Statistical analyses were performed by using SAS software version 9.4 (SAS Institute Inc, Cary, NC).
Study Oversight
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was approved by an independent ethics committee at each participating center or by a central institutional review board. All patients who were enrolled in this study provided written informed consent before participation. All authors had access to the study data and approved the final version of the manuscript.
Results
Patient Population and Disposition
Before September 15, 2016, a total of 667 treatmentexperienced (TE) patients with cirrhosis started treatment with LDV/SOF with or without ribavirin. Of those, 634 completed an assigned regimen, 22 were lost to post-treatment follow-up, and 2 died before evaluation of virologic data. The PP population with available virologic outcomes included 610 patients, including 128 patients who completed LDV/SOF for 12 weeks (58 without RBV, 70 with RBV), 490 who completed LDV/SOF for 24 weeks (426 without RBV, 64 with RBV), and 39 who completed LDV/SOF for other duration (34 without RBV, 5 with RBV) (Supplementary Figure 1) .
Baseline demographic, clinical, and laboratory characteristics of participants are summarized in Table 1 . All patients had GT1 HCV (66% GT1a), previously failed antiviral therapy, and had clinical evidence of cirrhosis.
The study population was 66% male, 24% aged 65 years or older, 75% white, 16% black or African-American, and 66% GT1a HCV. A significant proportion of enrolled patients had prior DAA failure (27.0%), a history of hepatic decompensation (40%), or history of orthotopic liver transplantation (OLT) (14%). Most patients had elevated liver function tests >2Â upper limit of normal, preserved liver synthetic function, and MELD score <10 (range, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
The disposition of all treated patients in this cohort is summarized in Table 2 . Of the 667 patients who started LDV/SOF with or without RBV, 26 (3.9%) discontinued treatment early, including 23 on LDV/SOF (4.4%) and 3 on LDV/SOF/RBV (2.1%). Ten patients (1.4%) discontinued because of AEs or death including 7 on LDV/ SOF (1.4%) and 3 on LDV/SOF/RBV (2.1%). Two patients (0.3%) discontinued early because of lack of efficacy, including 2 on LDV/SOF (0.4%) and none on LDV/ SOF/RBV. Fourteen patients (2%) discontinued for administrative reasons, including 14 on LDV/SOF (2.7%) and none on LDV/SOF/RBV. In total, 634 (95.1%) completed treatment, including 495 patients on LDV/ SOF (94.3%) and 139 patients on LDV/SOF/RBV (97.9%). Eight enrolled patients died during or after completion of treatment, including 6 on LDV/SOF (1.2%) and 2 on LDV/SOF/RBV (1.4%).
Treatment Response
The SVR12 rates for the PP population are shown in Figure 1 . Overall, 579 of 610 patients (93.8%) achieved SVR12, including 50 of 51 (98%) on LDV/SOF (12 weeks), 384 of 408 (94.1%) on LDV/SOF (24 weeks), 68 of 78 (97.1%) on LDV/SOF/RBV (12 weeks), and 57 of 60 (95%) on LDV/SOF/RBV (24 weeks). Patients with a history of hepatic decompensation were more likely to receive 24 weeks and/or RBV and had an overall SVR of Table 3 .
In the multivariable analysis, neither treatment duration nor the addition of RBV was predictive of SVR (P ¼ NS). Only patients with compensated rather than decompensated cirrhosis (OR, 2.41; 95% CI, 1.16-5.02), albumin !3.5 (OR, 3.15; 95% CI, 1.46-6.80), or total bilirubin 1.2 (OR, 3.34; 95% CI, 1.59-7.00) were associated with higher SVR (Figure 2) . A trend toward lower SVR was observed among male patients (OR, 0.49; 95% CI, 0.20-1.18) and patients with recorded use of proton pump inhibitors (OR, 0.56; 95% CI, 0.27-1.16), but this did not reach statistical significance.
Safety
Safety outcomes and AEs resulting in treatment discontinuation or death are summarized in Supplementary Tables 1 and 2 . Only 10 of 667 patients (1.4%) discontinued treatment prematurely because of an AE or death, with similar proportions observed among patients on LDV/SOF (7/525, 1.4%) and LDV/ SOF/RBV (3/142, 2.1%). Reasons for drug discontinuation from LDV/SOF, each reported in 1 patient, included atrioventricular block, metastatic breast cancer, hepatocellular carcinoma (HCC), intraventricular hemorrhage, multiorgan failure, septic shock, and subdural hematoma.
Reasons for drug discontinuation from LDV/SOF/RBV included hemolytic anemia, gastrointestinal perforation, and road traffic accident.
Seven patients (0.1%) who started LDV/SOF or LDV/ SOF/RBV died. Reported causes of death included metastatic breast cancer, HCC, intraventricular hemorrhage, multiorgan failure, septic shock, subdural hematoma, and road traffic accident. None of these events were considered treatment-related by the treating physician.
AEs were reported in 484 of 634 patients (76.8%) of the EP and were lower among patients on LDV/SOF (363/495, 73.3%) compared with those on LDV/SOF/ RBV (121/139, 87.1%). The most common AEs, reported in !10% of the patients, were fatigue, headache, and infections and infestations. Anemia events were reported in 49 patients overall (7.8%) and observed more commonly in patients on LDV/SOF/RBV (42/139, 30.6%) than in patients on LDV/SOF alone (7/495, 1.4%). Management of anemia events is summarized in Supplementary Table 3 .
Discussion
The results of this large, international observational real-world study of 667 HCV GT1 TE cirrhotic patients in HCV-TARGET demonstrate high efficacy and tolerability. Overall, the SVR12 rate in this traditionally difficult-totreat population was 93.8% (579/610), including 98% (50/51) in patients on LDV/SOF (12 weeks), 94.1% (384/408) in patients on LDV/SOF (24 weeks), 97.1% (68/70) in patients on LDV/SOF/RBV (12 weeks), and 95% (57/60) in patients on LDV/SOF/RBV (24 weeks). Neither treatment duration nor the addition of RBV was associated with higher SVR12. On multivariate analysis, only decompensated cirrhosis and markers of impaired liver function (albumin <3.5 and total bilirubin >1.2) were associated with lower SVR12. Both LDV/SOF and LDV/SOF/RBV were well-tolerated; only 10 of 667 12 A double-blind, placebocontrolled French trial of GT1 cirrhotic patients who failed telaprevir or boceprevir-based triple therapy regimens revealed similar SVR between LDV/SOF/RBV for 12 weeks (74/77, 96%) and LDV/SOF for 24 weeks (75/ 77, 97%), providing evidence for the comparability of the addition of RBV or extension of treatment to 24 weeks in this population.
14 A post hoc pooled analysis of seven phase 2 and 3 trials evaluating LDV/SOF or LDV/SOF/ RBV for GT1 cirrhotic patients revealed an overall SVR of 96% (493/573 patients) and 95% in TE patients. Small differences in SVR were observed between 12-week (95%) and 24-week (98%) duration, as well as between RBV-free (95%) and RBV-containing (97%) regimens. 15 Few real-world studies have evaluated the efficacy and safety of LDV/SOF with or without RBV in GT1 TE cirrhotic patients outside clinical trials. The Spanish HEPA-C cohort study of 937 GT1 patients (46.7% cirrhotic) revealed important differences in SVR by treatment duration and the addition of RBV. SVR12 was observed in 99 of 108 patients (91.7%) on LDV/SOF (12 weeks), 156 of 162 patients (96.3%) on LDV/SOF (24 weeks), 515 of 541 patients (95.2%) on LDV/SOF/RBV (12 weeks), and 120 of 126 patients (95.2%) on LDV/ SOF/RBV (24 weeks). 25 A retrospective analysis of national U.S. Veterans Affairs cohort data evaluating 17,487 patients undergoing oral DAA therapy also revealed important differences in SVR among GT1 TE cirrhotic patients. SVR12 was observed in 94.5% of 122 patients on LDV/SOF (12 weeks), 93.7% of 332 patients on LDV/ SOF (24 weeks), 89.4% of 668 patients on LDV/SOF/RBV (12 weeks), and 94.1% of 85 patients on LDV/SOF/RBV (24 weeks). 26 In addition, 2 meta-analyses evaluating the efficacy and safety of LDV/SOF with or without RBV for GT1 HCV, one pooling 7 studies (n ¼ 2626 patients) and a second pooling 10 studies (n ¼ 2248 patients), revealed the absence of improved SVR with the addition of RBV or treatment extension to 24 weeks, although subgroup analyses restricted to TE patients with cirrhosis were not performed. 27, 28 In this multinational real-world study in patients undergoing antiviral therapy in the United States, Canada, Germany, and Israel, PP analysis reveals excellent rates of SVR12 with LDV/SOF in GT1 TE cirrhotic patients, with or without RBV, and regardless of 12-or 24-week treatment duration. Only patients with decompensated cirrhosis or markers of impaired liver function demonstrated lower SVR with LDV/SOF for 12 weeks; therefore, these data support current guideline recommendations for LDV/SOF/RBV for 12 weeks (or LDV/ SOF for 24 weeks) in this population, although with careful consideration of baseline hemoglobin and/or risk factors for anemia. This study has several strengths. The HCV-TARGET consortium represents one of the largest reported realworld prospective observational cohorts of GT1 TE cirrhotic patients undergoing LDV/SOF treatment, with or without RBV, and for treatment duration of 12 or 24 weeks, with patient numbers exceeding those enrolled in clinical trials. This study included a large proportion of patients who were under-represented in clinical trials, including those who were DAA-experienced (27%), had a history of hepatic decompensation (40%), or cirrhosis post-OLT (14%). A significant proportion of patients were older than 65 years (24%), and a large proportion of the cohort were black or African-American (16%), a demographic group traditionally under-represented in randomized controlled trials, including the French SIRIUS protocol (3% black) 14 and phase 2 and 3 pooled post hoc analysis (5% black). 15 Because of prospective observational cohort design without randomization, selection bias in choice of regimen on the basis of characteristics predictive of treatment outcome could not be excluded. Furthermore, week 4 ontreatment HCV RNA values were not routinely collected, and data addressing pre-treatment IL28B genotype and NS5A resistance associated mutations were not available, although they may have provided valuable additional information to clarify the role of both baseline hosts and viral characteristics, as well as on-treatment viral kinetics, in DAA treatment outcomes in these patients. Finally, this analysis was restricted to patients who completed 12 or 24 weeks of LDV/SOF-based regimens PP, because a small number of patients who failed to complete a full treatment course or were lost to follow-up were excluded; therefore, attrition bias could not be excluded. However, sensitivity testing for SVR12 and subgroup analyses revealed no significant change in results.
In summary, in this large, multinational prospective observational cohort study, the all-oral combination of LDV/SOF was safe and effective for treatment of HCV GT1 infection in TE patients with both compensated and decompensated cirrhosis. No significant differences in SVR were observed in patients treated with or without RBV or treated with 12 or 24 weeks' duration. Although the SVR rates in this traditionally difficult-to-treat population were high and comparable to those reported in randomized controlled trials, lower SVR12 was observed in patients with decompensated cirrhosis and markers of impaired liver function (serum albumin <3.5, total bilirubin >1.2). Although new oral DAA regimens such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/ voxilaprevir have been associated with encouraging efficacy and safety in phase 3 registration trials among GT1 TE cirrhotic patients, ongoing concerns regarding the safety of protease inhibitor-based regimens in cirrhotic patients with impaired hepatic function remain. Additional datasets evaluating the role of treatment duration and RBV in nucleos(t)ide polymerase inhibitor/NS5A inhibitor combination regimens in this population are needed and continue to be of high clinical relevance. 
